An anticancer agent for cancers in which an abundance of cyclin D1 protein is greater than that in a control, the anticancer agent including a compound represented by the following Formula (1) as an active ingredient (in Formula (1), R1 to R11 each independently represent a hydrogen atom, an aliphatic group having 1 to 30 carbon atoms, or a group represented by Formula RCO—； (where, R represents an aliphatic group having 1 to 30 carbon atoms, or an aromatic group or heteroaromatic group having 1 to 10 carbon atoms)).
